Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19091638 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | March 2025 | July 2025 | Allow | 3 | 0 | 0 | No | No |
| 19088795 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | March 2025 | August 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19083274 | HETEROCYCLIC GLP-1 AGONISTS | March 2025 | December 2025 | Allow | 9 | 1 | 1 | No | No |
| 19076644 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | March 2025 | October 2025 | Allow | 7 | 1 | 1 | No | No |
| 19071155 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | March 2025 | August 2025 | Allow | 5 | 0 | 1 | No | No |
| 19069098 | MACROCYCLIC DERIVATIVE AND USE THEREOF | March 2025 | June 2025 | Allow | 3 | 0 | 1 | No | No |
| 19052553 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 1 | 0 | No | No |
| 19052557 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | February 2025 | September 2025 | Allow | 7 | 1 | 2 | No | No |
| 19038077 | 2,6,9-TRISUBSTITUTED PURINES | January 2025 | August 2025 | Allow | 6 | 2 | 1 | No | No |
| 19033289 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | January 2025 | July 2025 | Allow | 6 | 1 | 1 | No | No |
| 18972557 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | December 2024 | April 2025 | Allow | 5 | 0 | 1 | No | No |
| 18934931 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | November 2024 | February 2025 | Allow | 4 | 0 | 1 | No | No |
| 18884381 | AMIDO HETEROAROMATIC COMPOUNDS | September 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18882649 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | September 2024 | February 2025 | Allow | 5 | 0 | 1 | No | No |
| 18838246 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | August 2024 | April 2025 | Allow | 8 | 1 | 1 | No | No |
| 18800565 | IMIDAZOLO DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | August 2024 | November 2024 | Allow | 3 | 1 | 1 | No | No |
| 18730504 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | July 2024 | July 2025 | Allow | 12 | 0 | 1 | No | No |
| 18778527 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | July 2024 | October 2024 | Allow | 3 | 1 | 1 | No | No |
| 18775819 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | July 2024 | May 2025 | Allow | 9 | 1 | 1 | No | No |
| 18764004 | CRYSTALLINE SALT FORMS OF KAPPA OPIOID RECEPTOR ANTAGONIST AND PRODUCTS AND METHODS RELATED THERETO | July 2024 | August 2024 | Allow | 2 | 0 | 0 | No | No |
| 18724932 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | June 2024 | December 2024 | Allow | 6 | 0 | 1 | No | No |
| 18741974 | COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | June 2024 | October 2025 | Allow | 16 | 1 | 0 | No | No |
| 18741572 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | June 2024 | January 2026 | Allow | 19 | 1 | 0 | No | No |
| 18740233 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | June 2024 | May 2025 | Allow | 11 | 0 | 1 | No | No |
| 18675780 | CRYSTALLINE SOLID FORMS OF A BET INHIBITOR | May 2024 | July 2025 | Allow | 13 | 1 | 0 | No | No |
| 18668025 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18662990 | COMPOUNDS AS GLP-1R AGONISTS | May 2024 | July 2025 | Allow | 14 | 1 | 1 | No | No |
| 18661650 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | May 2024 | September 2024 | Allow | 4 | 1 | 1 | No | No |
| 18656052 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | May 2024 | September 2025 | Allow | 17 | 1 | 0 | No | No |
| 18651572 | SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS | April 2024 | October 2025 | Allow | 18 | 2 | 0 | No | No |
| 18644056 | KRAS G12D INHIBITORS | April 2024 | November 2025 | Allow | 19 | 1 | 1 | No | No |
| 18641842 | PHEBOX LIGANDS AND METHODS OF MAKING SAME | April 2024 | December 2024 | Allow | 8 | 0 | 0 | No | No |
| 18642602 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | April 2024 | December 2025 | Allow | 19 | 1 | 1 | No | No |
| 18639255 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | April 2024 | June 2024 | Allow | 2 | 0 | 0 | No | No |
| 18636832 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | April 2024 | October 2025 | Abandon | 18 | 2 | 1 | Yes | No |
| 18635839 | HETEROCYCLIC COMPOUND | April 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18630109 | THERAPEUTIC COMPOUNDS AND METHODS | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18623812 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18621480 | MATERIALS AND METHODS USEFUL TO INDUCE CANCER CELL DEATH VIA METHUOSIS OR AUTOPHAGY OR A COMBINATION THEREOF | March 2024 | October 2025 | Allow | 19 | 2 | 1 | No | No |
| 18612631 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | March 2024 | December 2024 | Allow | 9 | 2 | 1 | No | No |
| 18600352 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | March 2024 | June 2024 | Allow | 3 | 0 | 0 | No | No |
| 18600347 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | March 2024 | November 2024 | Abandon | 8 | 0 | 1 | No | No |
| 18596703 | METHODS OF MANUFACTURE AND SYNTHESIS OF FLUORESCENT DYE COMPOUNDS AND USES THEREOF | March 2024 | March 2026 | Allow | 24 | 2 | 1 | No | No |
| 18596024 | MULTICYCLIC COMPOUNDS | March 2024 | May 2024 | Allow | 3 | 0 | 0 | No | No |
| 18595898 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | March 2024 | July 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18584440 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | February 2024 | May 2024 | Allow | 3 | 1 | 1 | No | No |
| 18430456 | COMPOUNDS AND METHODS OF USE | February 2024 | September 2024 | Allow | 7 | 1 | 1 | No | No |
| 18430429 | COMPOUNDS AND METHODS OF USE | February 2024 | November 2024 | Allow | 10 | 1 | 1 | No | No |
| 18417159 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | January 2024 | May 2024 | Allow | 4 | 0 | 1 | No | No |
| 18413444 | KRAS MODULATORS AND USES THEREOF | January 2024 | October 2025 | Allow | 21 | 1 | 1 | No | No |
| 18413744 | PYRIDO[3,4-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINES AS CK2 INHIBITORS | January 2024 | August 2024 | Allow | 7 | 1 | 1 | No | No |
| 18538309 | PRO DRUGS OF PDE10 COMPOUNDS | December 2023 | September 2024 | Allow | 9 | 2 | 0 | No | No |
| 18533515 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | December 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18534520 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18527398 | STRUCTURAL ANALOG OF CYCLOTHEONELLAZOLE A, AND SYNTHETIC METHOD THEREFOR AND APPLICATION METHOD THEREOF | December 2023 | September 2024 | Allow | 10 | 0 | 1 | No | No |
| 18526922 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | December 2023 | March 2025 | Allow | 15 | 1 | 1 | No | No |
| 18525253 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | November 2023 | November 2024 | Allow | 12 | 1 | 0 | No | No |
| 18512361 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | November 2023 | April 2025 | Allow | 17 | 2 | 0 | No | No |
| 18510883 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | November 2023 | July 2024 | Allow | 8 | 1 | 1 | No | No |
| 18507566 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | November 2023 | May 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18504559 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | November 2023 | April 2025 | Allow | 18 | 1 | 0 | No | No |
| 18387680 | 4,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(3-PYRIDYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 0 | 1 | No | No |
| 18385992 | 9-(2-HYDROXYPYRIDIN-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 4 | 0 | 1 | No | No |
| 18558337 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | October 2023 | April 2025 | Allow | 18 | 0 | 1 | No | No |
| 18558188 | PHENANTHROIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | October 2023 | July 2024 | Allow | 9 | 0 | 1 | No | No |
| 18496504 | ISOINDOLINONE COMPOUNDS | October 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18495083 | COMPOUNDS AND METHODS OF PREPARING COMPOUNDS S1P1 MODULATORS | October 2023 | January 2026 | Allow | 27 | 1 | 1 | No | No |
| 18383448 | 2-[(1,3-BENZOXAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 0 | 1 | No | No |
| 18381016 | SYNTHESIS OF THIAZOLE DERIVATIVES | October 2023 | March 2024 | Allow | 5 | 1 | 1 | No | No |
| 18379891 | N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZO[D][1,3]DIOXOLE-5 CARBOXIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 1 | No | No |
| 18486126 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZO[D][1,3]DIOXOLE-5-CARBOXIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 1 | No | No |
| 18484675 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18554130 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | October 2023 | October 2025 | Allow | 24 | 1 | 0 | No | No |
| 18369069 | NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF | September 2023 | May 2025 | Allow | 20 | 1 | 1 | No | No |
| 18368244 | NMDA RECEPTOR MODULATORS AND USES THEREOF | September 2023 | March 2025 | Allow | 18 | 1 | 1 | No | No |
| 18367517 | GLP-1 Receptor Agonist and Composition and Use Thereof | September 2023 | February 2024 | Allow | 5 | 0 | 1 | No | No |
| 18244159 | Prevention, Prophylactic and Therapeutic Treatment of Autoimmune Diseases Including Multiple Sclerosis Using Novel Small Molecules and Compositions Thereof | September 2023 | September 2025 | Allow | 24 | 2 | 0 | No | No |
| 18460072 | METHOD FOR SYNTHESIZING (S)-NICOTINE AND INTERMEDIATE THEREOF | September 2023 | October 2023 | Allow | 2 | 0 | 0 | No | No |
| 18460464 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | September 2023 | September 2024 | Allow | 13 | 0 | 1 | No | No |
| 18239279 | 1,3-BENZOTHIAZOL-2-YL-N'-[(PYRIDINE-3-CARBONYL)OXY]ETHANIMIDAMIDE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | January 2024 | Allow | 4 | 1 | 1 | No | No |
| 18278656 | HETEROARYL DERIVATIVES AS APELIN RECEPTOR AGONISTS | August 2023 | February 2026 | Allow | 30 | 0 | 0 | No | No |
| 18237824 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | August 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18278325 | NOVEL BIOACTIVE SUBSTANCE EXHIBITING ANTIMALARIAL ACTIVITY, AND USE FOR SAME | August 2023 | March 2026 | Allow | 31 | 1 | 0 | No | No |
| 18453308 | BENZAMIDE ANTIBACTERIAL AGENTS | August 2023 | July 2025 | Allow | 22 | 1 | 1 | No | No |
| 18452278 | POLO LIKE KINASE 4 INHIBITORS | August 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18231628 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | August 2023 | January 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18276226 | 5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18363195 | THERAPEUTIC COMPOUNDS AND METHODS | August 2023 | January 2024 | Allow | 5 | 1 | 1 | No | No |
| 18362576 | KRAS MODULATORS AND USES THEREOF | July 2023 | December 2023 | Allow | 4 | 1 | 1 | No | No |
| 18274674 | BENZO SEVEN-MEMBERED RING BIFUNCTIONAL COMPOUND AND APPLICATION THEREOF | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18353718 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | July 2023 | June 2024 | Allow | 11 | 3 | 1 | No | No |
| 18350452 | HETEROARYL INHIBITORS OF PDE4 | July 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18349634 | ISOINDOLINONE COMPOUNDS | July 2023 | September 2023 | Allow | 3 | 0 | 0 | No | No |
| 18259422 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | June 2023 | November 2024 | Allow | 16 | 1 | 1 | No | No |
| 18258605 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18268681 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | June 2023 | October 2025 | Allow | 28 | 1 | 0 | No | No |
| 18335225 | SPIROCYCLIC COMPOUNDS | June 2023 | September 2023 | Allow | 3 | 0 | 0 | No | No |
| 18335480 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | June 2023 | August 2024 | Allow | 14 | 0 | 0 | No | No |
| 18332897 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | June 2023 | August 2023 | Allow | 2 | 0 | 0 | No | No |
| 18266077 | ISOXAZOLINE COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | June 2023 | February 2026 | Allow | 32 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HABTE, KAHSAY.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HABTE, KAHSAY works in Art Unit 1624 and has examined 2,591 patent applications in our dataset. With an allowance rate of 82.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 19 months.
Examiner HABTE, KAHSAY's allowance rate of 82.0% places them in the 54% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by HABTE, KAHSAY receive 1.10 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HABTE, KAHSAY is 19 months. This places the examiner in the 94% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +15.8% benefit to allowance rate for applications examined by HABTE, KAHSAY. This interview benefit is in the 56% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 40.6% of applications are subsequently allowed. This success rate is in the 92% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 70.5% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 166.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 91% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 92.3% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 86.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 49.2% are granted (fully or in part). This grant rate is in the 45% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 13.9% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 23.7% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.